# Pizarra — PT-pseudo_d95b3a02898e (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d95b3a02898e
Task: 1

Encounter: Urology - outpatient on 07 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 77-year-old male
  - PSA: 5.0 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 0.65 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 48.92 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8184269 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 5 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 49 mL. csPCa 0.82.

Vitals: weight 81 kg, height 168 cm, BMI 28.7, BP 137/70 mmHg, HR 61 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2023).

Chief complaint: Clinical reassessment follows recent MRI completion and ongoing PSA elevation.

History: Routine surveillance began after an initial PSA elevation was noted in early 2022. The 77-year-old subject carries a background of benign prostatic hyperplasia, chronic kidney disease with a baseline eGFR under 60 mL/min/1.73m², and well-controlled COPD treated with salbutamol PRN. Occupation: retired civil engineer. Residence: Lives alone. Daily habits include a 20-minute walk and complete alcohol abstinence. Tobacco use ceased in 2023 following a 13 pack-year exposure. Hearing loss remains stable, and he strongly prefers written clinical summaries. Surgical past includes a remote appendectomy during his thirties alongside conservative care for mild knee osteoarthritis. He denies bone pain, haematuria, or unexplained weight loss. An annual influenza vaccination was administered by the practice nurse recently.

Physical examination: DRE: The gland appears symmetrically enlarged, firm yet smooth, with absolutely no palpable nodules. General inspection shows a well-nourished individual free of acute distress. Lung fields are clear, cardiac rhythm regular. Abdominal palpation yields a soft, non-tender abdomen devoid of masses or organomegaly.

Patient info: retired civil engineer; Living with partner (unmarried); Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 5/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.48 +/- 0.17   (95% CI 0.16-0.81)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.17  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant further investigation?
  - previous_notes (get_previous_notes) -> What was the prior management context and agreed-upon surveillance pathway?

This case hinges on the PI-RADS score from the MRI and the management context provided in previous notes, as the current panel alone is insufficient to make a definitive biopsy decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which included a csPCa predicted probability of 0.8184269 and a PI-RADS score of 2. It failed to incorporate the context that the patient is biopsy-naive, the PSA velocity is 0.65 ng/mL/yr, and the specific PI-RADS 2 score relative to the PSA density (0.1 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.48 +/- 0.17. This suggestion could be wrong because the model is in a 'discuss' tier, meaning it genuinely cannot distinguish between biopsy and no biopsy based on the input. Furthermore, the prior did not account for the guideline criterion that mandates deferral when PI-RADS is 1-2, which aligns with the prior's suggestion, but it failed to weigh the rising PSA velocity, which suggests a need for re-evaluation.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant further investigation?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?

GUIDELINE ANCHOR
The guideline criterion states to defer biopsy when the mpMRI shows a PI-RADS 1-2 lesion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d95b3a02898e", "radiology_report": "Jeroen Bosch Ziekenhuis | 05 Jan 2025 | Multiparametric MRI Prostate\n\nClinical indication: Evaluation of elevated PSA (5.0 ng/mL) and prior PI-RADS 2 classification.\n\nFINDINGS: Dimensions of the gland stand at 38 x 52 x 41 mm, yielding a calculated volume of 48.92 mL. T2 sequences reveal a uniform peripheral zone, free of focal signal anomalies. No restricted diffusion appears on DWI, while DCE sequences show neither early nor persistent enhancement. A 4 mm benign prostatic utricle cyst resides at the midline apex. Seminal vesicles exhibit normal caliber and signal characteristics. Extraprostatic extension and suspicious lymphadenopathy are absent.\n\nIMPRESSION: PI-RADS 2. No PI-RADS 3+ lesion identified. PSA density: 0.1 ng/mL/mL. csPCa predicted probability 0.8184269."}
get_psa_trend
{"case_id": "PT-pseudo_d95b3a02898e", "psa_trend": [{"date": "May 2022", "val": 1.5}, {"date": "Apr 2023", "val": 1.3}, {"date": "Feb 2024", "val": 3.8}, {"date": "Jan 2025", "val": 5.0}]}
get_previous_notes
{"case_id": "PT-pseudo_d95b3a02898e", "previous_notes": [{"date": "09 Sep 2024", "author": "Dr. R. Visser (GP)", "text": "A routine follow-up visit addressed a rising PSA trajectory that hit 4.5 ng/mL during February 2024. After reviewing the incremental risk, a urology referral was secured for multiparametric MRI to characterize the gland. COPD management continued as before, with instructions to flag any fresh urinary symptoms immediately."}, {"date": "17 Jul 2023", "author": "Dr. R. Visser (GP)", "text": "The annual assessment recorded a steady PSA at 3.4 ng/mL, mirroring the prior year\u2019s results. Lower urinary tract symptoms persisted at a mild level (IPSS 5/35) and remained well-tolerated. Conservative monitoring proceeded, with a follow-up PSA check set for early 2024."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the specific questions for this decision were answered by the retrieved documents.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity of 0.65 ng/mL/yr, indicating a rising trend.
- Prior PSA history shows a significant rise from 1.3 ng/mL (Apr 2023) to 5.0 ng/mL (Jan 2025).
AGAINST sampling this patient now:
- mpMRI report shows PI-RADS 2, which falls into the deferral category per the protocol.
- Guideline criterion mandates deferral when PI-RADS is 1-2.
WHERE THIS LEANS
The evidence strongly supports deferral based on the PI-RADS 2 finding and the guideline criterion. This confirms the statistical prior's suggestion but is reinforced by the protocol.
LEAN: defer

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=no, evidence=no.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 2 finding from the MRI report and the guideline criterion mandating deferral for PI-RADS 1-2 lesions, strongly supports deferring biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is supported by the guideline criterion, which mandates deferral when the mpMRI shows a PI-RADS 2 finding. This finding was decisive, as it falls into the category requiring deferral. Although the PSA velocity was rising (0.65 ng/mL/yr), the PI-RADS 2 score, combined with the guideline, overrides the need for immediate sampling. The statistical prior suggested no biopsy, and the retrieved evidence confirmed this conclusion.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
